Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?

Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?

No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors. Unfortunately, only a minority of patients obtain a clinical benefit with immu...

Full description

Bibliographic Details
Main Authors: Ernesto Rossi, Giovanni Schinzari, Ilaria Grazia Zizzari, Brigida Anna Maiorano, Monica Maria Pagliara, Maria Grazia Sammarco, Vincenzo Fiorentino, Gianluigi Petrone, Alessandra Cassano, Guido Rindi, Emilio Bria, Maria Antonietta Blasi, Marianna Nuti, Giampaolo Tortora
Format: Article
Language:English
Published: MDPI AG 2019-07-01
Series:Cancers
Subjects:
immunotherapy
uveal melanoma
checkpoint inhibitors
PD-L1
nivolumab
pembrolizumab
ipilimumab
IDO
Online Access:https://www.mdpi.com/2072-6694/11/8/1055

Internet

https://www.mdpi.com/2072-6694/11/8/1055

Similar Items